Skip to main content
. 2020 May 19;7(4):1753–1763. doi: 10.1002/ehf2.12737

Figure 1.

Figure 1

Use and dosing of ACEI/ARB/ARNI (upper panels) and betablockers (lower panels) at baseline (left panels) and follow‐up (right panels) in the overall study cohort. ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor.